Skip to main content
Home
Issues
2024
November 2024 Vol 17, Payers' Guide to FDA Updates
2023
December 2023 Vol 16, Payers' Guide to FDA Updates
September 2023 Vol 16, Payers' Guide to FDA Updates
June 2023 - Vol 16 No 1
Issue Archive
Topics
Conference Correspondent
ESMO 2024 - Small Cell Lung Cancer
EHA 2024 – Wrap-Up: Myelodysplastic Syndrome
ASCO 2024 – Wrap-Up: Myelodysplastic Syndrome
Multimedia
Videos
Interview with the Innovators
Editorial Board
About
About AHDB
Contact Us
Permissions
Editorial Policies
Editorial Process
Advertising Policy
Subscribe
Home
Issues
2024
November 2024 Vol 17, Payers' Guide to FDA Updates
2023
December 2023 Vol 16, Payers' Guide to FDA Updates
September 2023 Vol 16, Payers' Guide to FDA Updates
June 2023 - Vol 16 No 1
Issue Archive
Topics
Conference Correspondent
ESMO 2024 - Small Cell Lung Cancer
EHA 2024 – Wrap-Up: Myelodysplastic Syndrome
ASCO 2024 – Wrap-Up: Myelodysplastic Syndrome
Multimedia
Videos
Interview with the Innovators
Editorial Board
About
About AHDB
Contact Us
Permissions
Editorial Policies
Editorial Process
Advertising Policy
Michael Kolodziej, MD
National Medical Director, Oncology Solutions, Aetna, Hartford, CT
Authored Items
Expectations of value-based cancer care
Michael Kolodziej, MD
Videos
Data to show impacts on collaborative approach to improve patient outcomes
Michael Kolodziej, MD
Videos
Payer/provider downside risk
Michael Kolodziej, MD
Videos
Payer/provider colaborations
Michael Kolodziej, MD
Videos
Are Aenta's colaboration targeting oncology providers
Michael Kolodziej, MD
Videos
Are there specific initiatives at Atena that other health plans can adopt for value based cancer care
Michael Kolodziej, MD
Videos
Last modified: January 15, 2015